logo-loader
CelLBxHealth PLC

CelLBxHealth PLC - Parsortix CTCs used for Brain Cancer detection

RNS Number : 9615P
CelLBxHealth PLC
11 August 2026
 

CelLBxHealth plc

("CelLBxHealth" or "the Company")

 

Parsortix CTCs used for Brain Cancer detection

 

·    Independent peer-reviewed study supports Parsortix® use in GBM

·    CTC-enriched GBM samples reflect matched tumour genomics

·    Findings suggest potential in GBM diagnosis and monitoring

·    Study aligned with CelLBxHealth own research data on GBM patient samples

 

Guildford, UK and Plymouth Meeting, USA - 11 August 2026 - CelLBxHealth plc (AIM: CLBX), a CTC intelligence company specialising in innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology, announces the publication of a peer-reviewed study in JCO Precision Oncology demonstrating the diagnostic and monitoring potential of Parsortix®-enriched CTCs in patients with glioblastoma ("GBM"), the most common aggressive malignant primary brain tumour in adults.

 

Key study findings

Researchers at Fondazione Pisana per la Scienza and Ospedali Riuniti di Livorno USL Toscana Nord Ovest, Italy, used the Parsortix® Platform to enrich CTCs from blood samples taken from 27 patients with GBM, alongside healthy controls and non-GBM brain lesion cases. Key findings include:

 

·    First proposed numerical CTC threshold for GBM, where >4 CTCs per 5 mL of blood helped distinguish patients with primary GBM from healthy controls, with 80% sensitivity and 77.3% specificity

·    Parsortix-enriched CTCs contained tumour-related mutations and chromosomal changes also seen in matched tumour tissue, indicating that the captured cells reflected the patient's tumour biology

·    Single-cell analysis showed that GBM CTCs were highly variable, reflecting known disease complexity

·    Radionecrosis and lymphoma samples yielded no detectable CTCs, supporting the use of CTC enumeration in differentiating tumour recurrence from treatment-related change

 

Although GBM rarely spreads outside the brain, this study adds to growing evidence that tumour-derived cells can be detected in the blood, opening the potential for minimally invasive molecular insight into GBM biology.

 

In-house GBM research study

At the annual Society for Neuro-Oncology meeting, held on 19-23 November in Hawaii, USA, the Company presented a poster entitled 'Unlocking the potential of liquid biopsy in glioblastoma: an extensive evaluation of circulating biomarkers.' CelLBxHealth's internal GBM research generated findings aligned with this independent study, supporting the potential of Parsortix®-enriched CTCs to provide tumour-related genomic information in a cancer where tissue biopsy is difficult and conventional monitoring approaches are limited.

 

Lavanya Sivapalan, PhD, CelLBxHealth Chief Scientific Officer, commented: "Glioblastoma remains one of the most difficult cancers to monitor, as repeat tissue sampling requires invasive neurosurgery and imaging can be difficult to interpret, particularly when assessing suspected recurrence. This study provides compelling independent evidence, aligned with our recently presented internal research, that Parsortix®-enriched CTCs can provide biologically relevant information in GBM. The proposed CTC threshold and genomic overlap with matched tumour tissue support further investigation of CTCs as a complementary liquid biopsy approach in this difficult-to-sample disease."

 

The peer-reviewed manuscript is available online: Lessi F. et al. (2026). Beyond the Brain: Circulating Tumor Cells as a Tool for Diagnosis and Monitoring. JCO Precision Oncology.

For further information:

CelLBxHealth plc

Jan Groen, Executive Chairman

investor@cellbxhealth.com via Walbrook PR



Cavendish (NOMAD and Broker)

Geoff Nash / Isaac Hooper (Corporate Finance)

Sunila de Silva (Corporate Broking)

Nigel Birks (Life Science Specialist Sales)

+44 (0) 20 7220 0500



Walbrook PR (Investor and Media Relations)

Paul McManus / Alice Woodings

Tel: +44 (0)20 7933 8780 or CelLBx@walbrookpr.com

Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654

Notes for editors

About CelLBxHealth plc

CelLBxHealth plc is a CTC intelligence company specialising in innovative circulating tumor cell (CTC) solutions for use in research, drug development, and clinical oncology. Its patent-protected Parsortix® platform harvests CTCs from blood and can be integrated with existing laboratory instruments for comprehensive downstream analysis - including whole-cell imaging, proteomic profiling, and full genomic workflows.

Commercial focus spans three revenue streams - Product Sales of the Parsortix platform and consumables through CRO and clinical lab partnerships, Laboratory Services including clinical trial support and assay development delivered from a GCLP-compliant UK facility, and Lab-Developed Tests (LDTs), pursued through a combination of strategic partnerships and in-house development.

For more information, visit https://cellbxhealth.com/.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCAKKBKCBKKKFD
NO INVESTMENT ADVICE

Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.

Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.

In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.

The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.

Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

FOR OUR FULL DISCLAIMER CLICK HERE

London BTC Company, CelLBxHealth, Anglo Asian Mining, Galliford Try,...

London BTC Company Ltd (LSE:BTC, OTCQB:VINZF) has staked 36 mineral claims at its new Black Star gold-silver project in Nevada, with surface samples returning up to 16.23 grams per tonne gold. It's the company's fourth Nevada project and sits just 16 miles from the 16.4 million ounce Hycroft...

on 07/15/2026

4 min read